Cellenkos® Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf, regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, announced that the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback